Home › Compare › KKOYF vs ABBV
KKOYF yields 4.73% · ABBV yields 3.06%● Live data
📍 KKOYF pulled ahead of the other in Year 3
Combined, KKOYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KKOYF + ABBV for your $10,000?
Kesko Oyj engages in the grocery trading business in Finland. It operates through Grocery Trade, Building and Technical Trade, and Car Trade segments. The company's Grocery Trade segment is involved in the wholesale and B2B trade of groceries; and the retail sale of the home and specialty goods. This segment operates approximately 1,200 K-food stores, including K-Citymarket, K-Supermarket, K-Market, and Neste K. Its Building and Technical Trade segment engages in the retail, wholesale, and B2B trade of building and home improvement, and electrical and HEPAC products, as well as trades in leisure goods. This segment operates retail store chains under the K-Rauta, K-Bygg, Byggmakker, and Onninen names, as well as leisure goods trade chains under the Intersport and Budget Sport names in Finland, Sweden, Norway, and the Baltic countries. The company's Car Trade segment imports, markets, and retails Volkswagen, Audi, SEAT, CUPRA, Bentley, and Porsche passenger cars, as well as Volkswagen and MAN commercial vehicles in Finland. This segment is also involved in car leasing activities; and the provision of repair and maintenance, spare parts, and accessories services, as well as charging network for electric vehicles under the K-Charge name in Finland. Kesko Oyj was founded in 1940 and is headquartered in Helsinki, Finland.
Full KKOYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.